OncoMatch/Clinical Trials/NCT07175220
Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects
Is NCT07175220 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including SHR2554; SHR-A2102 and SHR2554; Adabelimumab for locally advanced or metastatic non-small cell lung cancer.
Treatment: SHR2554; SHR-A2102 · SHR2554; Adabelimumab · SHR2554; SHR-1701 — Evaluate the safety, tolerability, and objective response rate (ORR) of SHR2554 tablets in combination with other anti-tumor treatments in subjects with locally advanced or metastatic non-small cell lung cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: any anti-tumor treatment
Lab requirements
Blood counts
Has a good level of organ function
Kidney function
Has a good level of organ function
Liver function
Has a good level of organ function
Has a good level of organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07175220 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior any anti-tumor treatment disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages